Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 16 | 18 | +2 |
| Shares | 63.4K | 138.6K | +75.2K (+118.7%) |
| Value | $241.5K | $345.2K | +$103.6K (+42.9%) |
New holders (7)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 41,427 | $103.2K | 0.00% |
| Vanguard Group Inc | 23,280 | $58.0K | 0.00% |
| Northern Trust Corp | 16,914 | $42.1K | 0.00% |
| Geode Capital Management, LLC | 12,417 | $30.9K | 0.00% |
| Jane Street Group, LLC | 10,743 | $26.8K | 0.00% |
| Wells Fargo & Company | 2,300 | $5.73K | 0.00% |
| UBS Group AG | 169 | $420 | 0.00% |
Sold out (5)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 16,815 | $72.1K |
| Sabby Management, LLC | 8,705 | $37.3K |
| GPS Wealth Strategies Group, LLC | 1,225 | $5.26K |
| Advisory Services Network, LLC | 59 | $253 |
| Wealthspire Advisors, LLC | 15 | $65 |